Introduction to CT of the Abdomen and Pelvis

Technical Considerations

When a request is presented for an abdomen-pelvis CT scan, the radiologist should assess the clinical problem to be evaluated by reviewing the available patient history and all pertinent available previous imaging studies. Medical history of importance to CT examination includes the current indication for the study, the risk of administering contrast agents, including history of allergic reactions or impaired renal function, the presence of cardiac or other diseases, past abdominal surgical procedures, history of malignancies and radiation therapy, and the findings and availability of previous imaging studies performed elsewhere. Previous imaging studies are reviewed to ensure that all previously identified abnormalities and questionable findings are appropriately reevaluated.

Decisions to be made to individualize the examination include:

• Area scanned: anatomic landmarks and scan extent.

• Radiation dose (tube current, peak tube potential), pitch, scan speed, rotation time specific to the size of the patient. Specific pediatric protocols should be used.

• Beam collimation (detector width and number of detector rows).

• Type and concentration of contrast agent to be administered: intravenous, oral, rectal, or intracavitary.

• Intravenous contrast agent concentration, administration rates, method of administration, and scan timing for arteriography and venography, or for arterial phase, venous phase, and delayed phase enhancement of solid organs and tissues.

• Slice thickness, reconstruction intervals, reconstruction planes, and three-dimensional image reconstructions.

Most institutions have developed standard protocols for a variety of indications, which depend in part on the scanner manufacturer and the number of detector rows. These may be modified as needed to appropriately address the patient problem.

Gastrointestinal Contrast Agents

Nearly all CT scans of the abdomen require the administration of intraluminal contrast agents to demonstrate the lumen of and to distend the gastrointestinal tract. Radiopaque agents may be dilute concentrations of barium or iodinated contrast agents. Iodinated agent concentrations of 1% to 3% are optimal for intraluminal opacification for CT, as compared with the 30% to 60% solutions used for fluoroscopy. Barium mixtures and water-soluble iodinated agents are equally effective as opaque oral contrast agents.

Air and water are excellent as low-attenuation contrast agents. Carbon dioxide is preferred for instillation into the rectum to insufflate the colon for CT colonography. Effervescent crystals with a small volume of water may be given orally to distend the stomach with gas. Water serves as an excellent low-density contrast agent for the upper gastrointestinal tract. Urine in the distended bladder provides excellent contrast for bladder lesions. Patient preparation may include having the patient avoid urination or clamping an indwelling Foley catheter. Low-attenuation barium-based contrast agents are used for CT enterography.

Intravenous Contrast Agents

Intravenous contrast agents improve the quality of abdominal CT by opacifying blood vessels, increasing the CT attenuation of abdominal organs, confirming perfusion, and increasing image contrast between lesions and normal structures. MDCT allows multiphase imaging to demonstrate the passage of contrast agent through the arterial system, organs and tumors, and the venous system. Delayed images show contrast agent excretion by the kidneys, late enhancement, or prolonged retention of intravenous contrast agent in organs and lesions. For most applications, intravenous contrast agents are administered by power injectors that provide accurate control of the rate and volume of administration.

Low-osmolarity “nonionic” iodine-based agents are the intravenous contrast agents of choice for most abdominal scanning because of their lower rate of adverse reactions. Sterile iodinated contrast agents approved for intravenous injection can be injected into indwelling catheters, drainage tubes, sinus tracts, and fistulas to evaluate the extent of disease. For intravenous administration, iodine concentrations of 60% and 75% are most commonly used. Older ionic contrast agents of higher osmolality are no longer used for intravascular injection because of significantly higher rates of adverse reactions. However, these cheaper ionic agents may be used for intracavitary injection, where adverse reactions are rare. For injection into the bladder for CT cystography, or through indwelling catheters for demonstration of fistulas, sinus tracts, or abscess cavities, the contrast agent is usually diluted to an iodine concentration of 2% to 3%.

Although detailed review of adverse reactions and safe use of intravenous contrast agent is beyond the scope of this text, patient safety is always the first priority. Adverse reactions associated with intravenous contrast agent administration include anaphylaxis, cardiac and respiratory arrest, nephrotoxicity, and hives. The reader is referred to the Suggested Reading section for several excellent reviews on safe use of iodinated intravenous contrast agents.